We evaluated the efficacy and toxicity of adding 9 Gy of total body irradiation (TBI), in three single daily fractions of 3 Gy, to the reduced intensity regimen of fludarabine 30 mg/m 2 i.v. Â 4 days and melphalan 140 mg/m 2 i.v. Â 1 day in advanced pediatric hematologic malignancies. Twenty-two acute lymphoblastic leukemia (ALL), six acute myeloid leukemia (AML), and one non-Hodgkin lymphoma patients were transplanted. Of these, 13 were beyond second remission, and five had prior hematopoietic stem cell transplant (HSCT). Twenty-one donors were unrelated, of which 19 were from cord blood (CB) units. Three of the eight related donors were genotypically disparate. Oral mucositis and diarrhea were the most common toxicities. Twenty-seven patients achieved neutrophil engraftment (median 16 days), and 23 had platelet engraftment (median 42 days). One patient had primary graft failure. Seven patients died of non-relapse causes in the first 100 days. With a median follow-up of 52 months, seven of 22 ALL, five of six AML, and one of one lymphoma patients are alive and in remission. The regimen of TBI, fludarabine, and melphalan allows the engraftment of allogeneic hematopoietic stem cells (including mismatched CB). It was fairly well tolerated in pediatric patients, even for second transplants. Its efficacy requires further evaluation.
Introduction
Hematopoietic stem cell transplantation (HSCT) using a myeloablative preparative regimen can be curative for various pediatric hematologic malignancies. Unfortunately, this treatment strategy is associated with a significant risk of transplant-related mortality (TRM), especially if the disease is advanced, when alternative donors are used, or when a second HSCT is done. For example, in 50 children with leukemia who received unrelated-donor bone marrow transplant (BMT), the 100-day TRM was 36%. 1 Complication rate is also high after unrelated donor cord blood transplants (CBT). Rocha et al. reported adverse events in 39% of the 99 CBT in the Eurocord Registry. 2 Fludarabine (FLU) is a nucleoside analog with potent T cell immunosuppressive activity comparable to that of cyclophosphamide. 3, 4 It potentiates the cytotoxic effect of irradiation by increasing the amount of residual DNA and chromosome damage. 5 Melphalan (MEL) is an alkylating agent with demonstrated activity in acute leukemia. 6 A reduced-intensity preparative regimen of FLU and MEL leads to durable engraftment in sibling and unrelated HSCT in adult patients. [7] [8] [9] However, this approach has not been evaluated in childhood leukemia.
Total body irradiation (TBI) is an important component of HSCT conditioning. For childhood acute lymphoblastic leukemia (ALL), TBI-containing regimens have produced better transplant outcome compared to that after chemotherapy-only regimens. 10, 11 However, the optimal dose of TBI for HSCT has not been defined. Dosage ranging from 5.5 Gy as a single exposure to 15.75 Gy in multiple daily fractions has been used. 12, 13 In general, higher TBI doses are used for advanced leukemia or HLA-disparate grafts. Regimens with higher dose of TBI reduced the rate of leukemia recurrence, but were associated with an increased incidence of non-relapse mortality, so that the overall survival of the patient population was not improved. 13 The incidence of long-term side effects from TBI is related to the absolute dose administered and the dose rate at which it is delivered. Side effects such as growth retardation and endocrine insufficiency are of particular concern in children. Currently the TBI doses commonly used in pediatrics are 12-14.4 Gy given over 3-4 days. 1, 9, 10 A lower dose of TBI is desirable if other agents in the regimen can provide adequate immunosuppression, maintain the anti-neoplastic efficacy and do not cause excessive toxicity. FLU appears to fulfill some of these criteria. This study evaluated a novel combination of 9 Gy of fractionated TBI, FLU and MEL. We hypothesized that the inclusion of FLU would allow a reduction in the dose of TBI and still be sufficient for the engraftment of HSC of various sources. The goals were to determine the toxicity, engraftment potential, and efficacy of this regimen for advanced pediatric hematologic malignances.
Patients and methods

Patient and donor selection
Leukemia or lymphoma patients 5-21 years of age with recurrent disease or with adverse cytogenetic abnormalities in first complete remission were eligible. They also met the following criteria: left ventricular ejection fraction 450%, serum creatinine and bilirubin levels not more than twice the upper limit of normal for age, serum alanine aminotransferase level not more than three times the upper limit of normal, human immunodeficiency virus antibody negative, and Lansky's performance status 470%. Patients who received a transplant during the first or second complete remission of acute leukemia from an HLAidentical donor (related or unrelated) were considered standard risk; the rest of the patients were regarded as high risk. The protocol was approved by the institutional review board of The University of Texas, M.D. Anderson Cancer Center, and written informed consent was obtained from parents or guardians for all patients.
The target cell dose for marrow infusion was 3 Â 10 8 total nucleated cells per kg, and that of peripheral blood stem cells was 4 Â 10 6 CD34 cells per kg of recipient's weight. Unrelated umbilical CB units were selected according to the number of nucleated cells per recipient's body weight and HLA compatibility (HLA-A and -B by serology and HLA-DRB1 by high-resolution DNA typing). The criteria used was a minimum of 2.5 Â 10 7 nucleated cells per kg and no more than three HLA mismatches, although the cell-dose requirement might be lowered for urgent cases.
Conditioning regimen and transplantation
The conditioning regimen consisted of TBI single daily fractions of 3 Gy on days À7 to À5 (total dose of 9 Gy), with lung shielding on the third fraction; FLU 30 mg/m 2 i.v. over 2 h daily on days À4 to À1 (total dose 120 mg/m 2 ); and MEL 140 mg/m 2 i.v. over 30 min once on day À1. Antithymocyte globulin or corticosteroids were not used. Bone marrow, blood stem cells, or umbilical CB from related or unrelated donors was infused for hematopoietic reconstitution on day 0. No T cell depletion was performed.
GVHD prophylaxis
For the prevention of acute graft-versus-host disease (GVHD), patients received tacrolimus at 0.03 mg/kg/day i.v. by continuous infusion starting on day À2, and methotrexate 5 mg/m 2 i.v. on days 1, 3 and 6. Recipients of unrelated donor blood stem cell (but not CB) transplants, and genotypically disparate related donor grafts were given a fourth dose of methotrexate on day 11. Following engraftment and when the patient was able to eat, tacrolimus was converted to oral administration through day 100 and tapered thereafter.
Supportive care
Patients were monitored and received supportive care according to standard procedures in our institution. Filgrastim at a dose of 5-10 mg/kg/day was given subcutaneously from day þ 1 until the neutrophil count exceeded 1.5 Â 10 9 /l for 3 days. Infection prophylaxis during the peritransplant period consisted of acyclovir 5 mg/kg i.v. every 8 h and fluconazole 6 mg/kg i.v. or orally once a day. For recipients of alternative donor transplant, intravenous gamma globulin 200 mg/kg was given weekly to day 100, and monthly thereafter to 1 year. Once engraftment occurred, the patients received pneumocystis prophylaxis, and CMV-seropositive patients who received alternative donor grafts were placed on ganciclovir, 5 mg/ kg/day i.v. to day 100.
Toxicity grading
Regimen-related toxicity (RRT) was graded as described, 14 except that death after day 28 resulting from RRT was also scored as grade 4. The maximum toxicity was the highest recorded in any individual organ system, and the cumulative toxicity was the sum of the highest scores recorded for all eight organ systems. Adverse events attributed to culture-documented infection, bleeding, and other medications, or GVHD were not scored as RRT.
Assessment of engraftment and response
Myeloid recovery was defined as the first of three consecutive days with an absolute neutrophil count X0.5 Â 10 9 /l, and platelet recovery was defined as the day the platelet count was X20 Â 10 9 /l with no platelet transfusions the following week. Bone marrow aspirates were examined for morphology and chimerism at 1, 3, 6, 12, 18 and 24 months after transplant. A complete remission was defined as a neutrophil count of 40.5 Â 10 9 /l, no circulating blasts in the peripheral blood, and o5% blasts in the bone marrow. Hematopoietic chimerism was evaluated by fluorescence in situ hybridization with a Y chromosome probe for sex-mismatched transplants or by PCR-based microsatellite polymorphism analysis. Diagnosis of GVHD was based on clinical and histological data. GVHD was graded according to the consensus criteria. 15 Statistical analysis All patients were followed to 28 February 2005 . Actuarial estimates of time to engraftment, acute GVHD, relapse, death, and treatment-related mortality (non-relapsed death) were calculated according to the method of Kaplan and Meier. Confidence levels were calculated using the Number Cruncher Statistical Software 2004 (NCCS, Kayville, UT, USA). Medians were compared using the Mann-Whitney U-test, and the signed rank test was used to compare matched samples. All P-values were two-tailed, and a P-value o0.05 was considered significant. Table 1 . Of the eight related HSCT transplants three donors were genotypically disparate with their recipients: one was a phenotypically identical mother, one was one-HLA antigen-mismatched sibling, and one was a haplotype-mismatch sibling (the recipient being HLA homozygous). All 19 unrelated CB units were mismatched with the recipients: five at one, 13 at two, and one at three HLA loci or alleles. All three patients transplanted in CR1 had Ph þ ALL. Five patients received this regimen for a second HSCT.
Results
Patient characteristics
Engraftment, graft-versus-host disease, and regimen-related toxicity The median cell dose for the marrow and blood stem cell grafts were 3.98 Â 10 8 total nucleated cells and 5.5 Â 10 6 CD34 cells/kg, respectively. The median pre-thawed nucleated cell dose of UCB transplant was 4.9 Â 10 7 (range 1.8-17.4) per kg.
Twenty-seven patients achieved ANC engraftment after a median time of 16 days (range 11-35), and 23 also had platelet engraftment at a median of 42 days (range 14-200). One CB patient had primary graft failure and one MUD recipient died of hepatic veno-occlusive disease (VOD) before engraftment. No mixed chimerism or secondary graft failure was encountered in the remaining patients. The regimen was well tolerated, with grade I and II oral mucositis and diarrhea the most common side effects seen ( Table 2) .
Thirteen of 27 (48.1%) evaluable patients developed acute GVHDXgrade II: of these six (22.2%) were grade III and IV. Three patients had chronic GVHD. There were seven deaths in the first 100 days due to GVHD (2), adenovirus infection (2), interstitial pneumonitis (1), VOD (1), and graft failure (1); all fatalities occurred in patients with ALL.
Infection
During the first 100 days after transplant, 23 patients had positive blood cultures. Of these 10 were coagulase-negative staphylococci and five were alpha-hemolytic streptococci. CMV antigenemia assays were positive in nine patients, adenovirus was isolated in two, and parainfluenza type II was identified in one patient. Three patients had hemorrhagic cystitis associated with polyomavirus. Fungal infections were present in four patients.
Response and survival
Five patients (three ALL, two AML) had active disease at the start of preparative regimen, with 6-38% blasts (median 28%) in the bone marrow. All achieved complete remission on the day 30 bone marrow examination. Their subsequent remissions lasted 240-1662 (median 367) days.
The cumulative survival for the 16 patients transplanted in CR1 and CR2 is 49% (95% CI, 24-74%), and that of the 13 patients with advanced disease status at the time of transplant is 37% (95% CI, 10-64%). Eight and five patients, respectively are alive and currently in CR after HSCT. This includes eight of the 19 CBT recipients. According to the diagnosis, eight of 23 patients with lymphoid malignancies and four of six patients with AML are in continuous complete remission. Nine patients relapsed at a median of 8 months post transplant (range 2-54). Eight of them succumbed to their disease. One AML Sixteen patients died. Besides the seven non-relapse deaths mentioned above, another patient died of interstitial pneumonitis and GVHD 4 months after a MUD blood stem cell transplant. With a median follow-up of 52 (range 23-86) months, the 3-year Kaplan-Meier estimate of survival for ALL is 31% (95% CI, 12-51%) and for AML is 83% (95% CI, 54-100%). At the time of reporting seven of 22 ALL, five of six AML, one of one lymphoma patients remain alive and in remission.
Discussion
Advanced pediatric hematologic malignancies are aggressive diseases and may require intensive cytoreduction in the immediate pre-transplant period. We tested the addition of 9 Gy of TBI to the FLU and MEL regimen to evaluate its tolerability, engraftment efficacy, and antineoplastic activity. Adult patients not qualified for myeloablative conditioning were able to tolerate the reduced intensity regimen of FLU-MEL, with a 100-day non-relapsed mortality of 11-37%. [7] [8] [9] The major toxicity was gastrointestinal. In this series, children with advanced hematologic malignancies tolerated the TBI, FLU, and MEL regimen relatively well. The TRM rate of 24% was comparable to other series with patients of similar disease status. 16, 17 Grade I and II mucositis and diarrhea were the most frequent side effects. Patients recovered quickly and the median time to discharge was day þ 22 for the non-CBT recipients. All five patients who had prior HSCT were discharged alive. Each of them had previously received busulfan-containing, chemotherapy-only preparative regimens. Therefore, the combination of TBI, FLU, and MEL may provide an alternative, non-cross resistant regimen for patients, who relapse after high-dose chemotherapy. We did encounter two cases of severe (one fatal) VOD. It is of note that inclusion of FLU in a 2 Gy of TBI reducedintensity regimen was associated with a slight increase in risk of hepatic injury, although most cases were from cholestasis owing to GVHD and/or sepsis. 18 Our regimen was not tolerated as well in adult patients, a concurrent study in our adult acute leukemia patients was stopped early because of excessive oral mucositis.
Unrelated donor CBT is associated with a significant engraftment failure rate. 2, 19, 20 This unfavorable outcome is due to a low cell dose infused and the frequent HLA disparity between the donor and the recipient. To circumvent this problem higher dose of TBI and anti-T cell antibody, with or without corticosteroid, are commonly included in the CBT preparative regimens. Despite these measures, up to 20% of CBT might not engraft. 19, 20 In this series, 18 of 19 mismatched unrelated donor CBT were engrafted after TBI-FLU-MEL, despite adverse features associated with lower engraftment rate: that is, an older age (median 8 years), and more than one antigen-disparity (74%). The inclusion of FLU in CB transplantation appeared to improve the engraftment rate. 20, 21 Of note, Miyakoshi et al. reported successful engraftment of CB grafts in 26 of 30 adult patients after conditioning with 125 mg/m 2 of FLU, 160 mg/m 2 of MEL, and 4 Gy of TBI. The 100-day non-relapse mortality was 27%. 22 The intense immunosuppression used to promote CB engraftment may increase the incidence of post transplant infections. We showed that a satisfactory engraftment rate could be achieved without the use of anti-T cell antibody and corticosteroid. Whereas the exclusion of these agents is theoretically desirable, we did not find the incidence of infections to be significantly reduced. This may reflect the small number of patients transplanted and the advanced stages of disease in our patient population.
The efficacy of TBI-FLU-MEL combination is comparable to other standard preparative regimens in the treatment of advanced pediatric hematologic malignancies. The relapse rate in ALL patients was high, but was similar to that of other reports. 1, 11, 23 Davies et al. reported a 2-year disease-free survival of 30% in 35 ALL children undergoing unrelated donor BMT. 1 In another series 31% (28 of 88) of ALL patients survived for 1-10 years. 11 The outcome of unrelated CBT is not different. The Eurocord registry reported a 2-year leukemia free survival of 36% in children transplanted in remission, and 15% in those transplanted in relapse. 24 It is possible that the dose of 9 Gy of TBI in this regimen was not adequate for the control of ALL. In view of the tolerability of the current regimen, one modification may be to increase the TBI dose to the more standard 12 Gy. Fludarabine has been associated with pulmonary toxicity. 25 Although we did not encounter unusual lung complications with 9 Gy of TBI, caution should be used prior to extrapolating this data to a higher dose of irradiation. The disease-free survival rates after HSCT in children with AML in CR2 was reported at 58%, 26 whereas that of advanced diseases ranged from 24-51%. 27 , 28 Michel et al. 29 reported a 2-year leukemia-free survival of 42% after unrelated donor CB transplant for childhood AML. We are encouraged by the outcome of the AML patients. As this regimen was fairly well tolerated, it may provide a platform for the more potent graft-versus-leukemia effect to operate in myeloid malignancies. However, the small number of cases precludes definitive conclusion and the efficacy of this regimen in AML requires further evaluation.
In conclusion, the addition of 9 Gy of TBI to FLU and MEL leads to successful engraftment of allogeneic HSC (including 1-2 antigen-mismatched-unrelated CB units) in heavily pretreated pediatric patients with hematologic malignancies, without the inclusion of ATG. The regimen was relatively well tolerated. Owing to the heterogeneity of the patient population and stem cell source, a definite conclusion on the efficacy of this regimen cannot be drawn and further evaluation is required.
